Why Is Nivolumab Used After Esophageal Cancer Surgery?

It can be confusing to learn that you may need more treatment after a major surgery to remove your esophagus. Before surgery, you likely received chemotherapy and radiation. Surgery removed the visible tumor, but sometimes the pathology report shows that microscopic cancer cells remained in the removed tissue ^[1]. This means there is a higher chance that microscopic cells could still be in your body, increasing the risk of the cancer returning ^[2].

Nivolumab is an immunotherapy drug that may be recommended after surgery (as “adjuvant therapy”) to help your immune system recognize and control these remaining cells, lowering the risk of recurrence ^[2].

Understanding “Residual Disease”

After your esophagectomy, the removed tissue is sent to a lab to be examined under a microscope. If the pathologist finds live cancer cells in the tumor (noted as ypT) or in the nearby lymph nodes (noted as ypN), this is called residual disease ^[1].

Having residual disease does not mean the surgery failed or that the surgeon left visible cancer behind. Instead, it indicates that the initial chemotherapy and radiation did not completely eliminate the cancer cells in that area ^[1]. While this finding raises the chance that the cancer could return, it does not prove that cancer has spread to other parts of your body.

Nivolumab may be recommended if you had a complete surgical removal where the edges of the removed tissue were clear of cancer (known as an R0 resection or “clean margins”), but residual disease was still present ^[2][1]. Doctors cannot tell whether hidden cells are actually present in your body right now, but they know that residual disease is a marker of increased risk.

Is Nivolumab Right for Me?

Nivolumab is not automatically recommended for everyone who has esophageal surgery. Your oncologist will consider several factors through shared decision-making:

• Your specific cancer: The treatment is indicated for patients who had pre-surgery chemoradiation and an R0 resection, but still had residual disease ^[2].
• Your recovery: How well you are healing from surgery, including your current energy levels, wound healing, and ability to get adequate nutrition.
• Your health history: Conditions like autoimmune diseases or prior organ transplants can make immunotherapy riskier, as the drug can cause the immune system to attack healthy tissue ^[3].

How Nivolumab Works

Nivolumab is a type of immunotherapy called a checkpoint inhibitor; it is not traditional chemotherapy. Cancer cells can hijack a natural pathway in your body (the PD-1 pathway) to put the “brakes” on your immune system, making themselves invisible to your natural defenses ^[4]. Nivolumab blocks this pathway, essentially taking the brakes off your immune system ^[4]. This may help your own T-cells (a type of white blood cell) recognize and attack any remaining cancer cells.

The Evidence: The CheckMate 577 Trial

The medical evidence for using adjuvant nivolumab comes from a major clinical study called the CheckMate 577 trial ^[2]. This global study included patients with esophageal or gastroesophageal-junction cancer who had residual disease after chemoradiation and an R0 surgery ^[1]. They received either nivolumab or a placebo (an inactive treatment) for up to one year.

The trial showed that nivolumab delayed the time until the cancer returned:

• Median Disease-Free Survival: This is a group statistic measuring the time until the cancer returned or the person died. The median was 22.4 months for those taking nivolumab, compared to 11.0 months for those on the placebo ^[2]. (A median means half the people in that group went longer without an event, and half went a shorter time.)
• Relative Risk Reduction: Nivolumab lowered the relative risk of recurrence or death by roughly 31% compared to the placebo ^[2]. This is a relative reduction, not a guarantee that the cancer will never return.

While nivolumab significantly improves disease-free survival, researchers have noted that a definitive improvement in overall survival (the total time patients live) has not been statistically confirmed for all patients in long-term follow-ups of this trial ^[5].

Logistics of Treatment

Nivolumab is typically given through an intravenous (IV) infusion for up to one year ^[2]. The schedule may vary; it is often given every two weeks initially, and sometimes shifted to every four weeks ^[1]. Your care team will monitor your blood work regularly before each infusion. Treatment might be paused or permanently stopped if you experience severe side effects or if the cancer returns.

Balancing Benefits and Risks

Because nivolumab ramps up your immune system, it can cause your immune system to mistakenly attack healthy organs ^[3]. In the CheckMate 577 trial, about 13% of patients taking nivolumab experienced severe, treatment-related side effects, compared to 6% of patients on the placebo, and approximately 9% had to stop the drug entirely because of side effects ^[2].

Common side effects include fatigue, rash, diarrhea, nausea, muscle pain, and cough ^[1].

Urgent Warning Signs of Immune-Related Side Effects:
Many side effects can be treated if caught early, but some can be serious, permanent (such as requiring lifelong hormone replacement), or life-threatening if they cause severe inflammation of the lungs, bowel, liver, or kidneys ^[3].

Do not wait for your next appointment. Contact your oncology team promptly or seek emergency care if you experience any new or worsening symptoms, including:

• Lungs: New or worsening cough, shortness of breath, or chest pain.
• Bowel: Persistent diarrhea, severe abdominal pain, or blood/mucus in your stool.
• Liver: Yellowing of your skin or eyes, dark urine, or severe right-sided abdominal pain.
• Hormone Glands: Extreme fatigue, severe headaches, dizziness, or fainting.
• Kidneys: Reduced urination or new swelling in your ankles.
• Skin: A severe or widespread rash, or skin peeling.

Always ensure you have the 24-hour contact number for your oncology team and know when you should go to the emergency room.